Keywords
Depressive Disorder ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

233 Search results.

Measurement Instrument Database for the Social Science (MIDSS) - The Brief Edinburgh Depression Scale (BEDS)

- 9/30/20 - 1 form, 2 itemgroups, 7 items, 1 language
Itemgroups: General Information, BRIEF EDINBURGH DEPRESSION SCALE
Lloyd-Williams, M., Shiels, C., Dowrick, C. (2006). The Brief Edinburgh Depression Scale (BEDS). Measurement Instrument Database for the Social Science. Retrieved 30.09.2020, from www.midss.ie Key references: Lloyd-Williams, M., Shiels, C., Dowrick, C. (2007). The development of the Brief Edinburgh Depression Scale (BEDS) to screen for depression in patients with advanced cancer. Journal of Affective Disorders, 99(1-3), 259-264. Primary use / Purpose: The Brief Edinburgh Depression Scale (BEDS) is a 6-item inventory rated on a 4 point Likert-type scale. Its purpose is to briefly and accurately measure depression in those in the advanced stages of cancer. Background: Depression and reduced quality of life have long been recognized as serious problems in the later stages of cancer. These mood states are commonly infered from physical symptoms such as weight loss, loss of appetite, or/and sleep disturbance. However, subjective measures are often ignored. The Brief Edinburgh Depression Scale (BEDS) aims to address this limitation by instead ignoring somatic symptoms, focusing only on subjective feelings of worth and sadness et alia. In its brief form the BEDS also has the advantage of being quick and easy to use which is an important consideration when dealing with terminally ill patients. Psychometrics: The psychometric properties of the Brief Edinburgh Depression Scale (BEDS) are discussed in Lloyd-Williams, Shiels, & Dowrick (2007). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.328 Scoring: Score of 6/18 is indicative of depression Background: The development of a brief valid tool to screen for depression in patients with advanced cancer is important. This paper reports data on the psychometric properties of the Brief Edinburgh Depression Scale Method: Two hundred and forty six patients who fulfilled the inclusion criteria completed the 10 item EDS and Present State Examination. Results: Factor extraction revealed 6 items from the ten item EDS. The most valid cut-off for defining a case, using the PSE diagnosis as the “gold-standard”, was a score of 6 out of 18 on the Brief Edinburgh Depression Scale which gave a sensitivity of 72% and specificity of 83% with a PPV of 65.1% and NPV of 87.1%. Conclusions: The six item EDS is a brief and sensitive method of screening for depression in advanced cancer patients - this novel use of the Edinburgh depression scale may have a significant impact on the assessment and thus management of this distressing symptom

Eligibility Unipolar Major Depressive Disorder NCT01875419

- 12/31/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Non-invasive Brain Stimulation and Cognitive Processing in Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01875419

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Investigator's Signature

- 12/8/19 - 1 form, 2 itemgroups, 4 items, 1 language
Itemgroups: Administrative documentation, Investigator Signature
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Investigator Comment Log

- 12/8/19 - 1 form, 2 itemgroups, 3 items, 1 language
Itemgroups: Administrative documentation, Clinical Investigators, Comment
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Unscheduled

- 12/8/19 - 1 form, 7 itemgroups, 45 items, 1 language
Itemgroups: Administrative documentation, Laboratory Procedures, Hematology finding, Laboratory Procedures, Chemistry, Clinical, Urinalysis, Vital signs, 12 lead ECG, 12 lead ECG, Abnormality
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Study Conclusion

- 12/8/19 - 1 form, 2 itemgroups, 6 items, 1 language
Itemgroups: Administrative documentation, Clinical Trials, Conclusion
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Pregnancy Information

- 12/8/19 - 1 form, 2 itemgroups, 3 items, 1 language
Itemgroups: Administrative documentation, Pregnancy, Information
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Serious Adverse Event (SAE)

- 12/8/19 - 1 form, 13 itemgroups, 42 items, 1 language
Itemgroups: Administrative documentation, Serious Adverse Event, Serious Adverse Event, Seriousness of Adverse Event, Serious Adverse Event, Demography, Serious Adverse Event, Relationships, Experimental drug, Serious Adverse Event, Etiology aspects, Serious Adverse Event, Disease, Serious Adverse Event, Risk factors, Serious Adverse Event, Concomitant Agent, Serious Adverse Event, Experimental drug, Details, Serious Adverse Event, Diagnostic Procedure, Serious Adverse Event, Comment, Serious Adverse Event, Investigator Signature
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Non-Serious Adverse Events (NSAE)

- 12/8/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Administrative documentation, Non-serious Adverse Event
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Concomitant Medications

- 12/8/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Administrative documentation, Concomitant Agent
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - PGx - Pharmacogenetic Research

- 12/8/19 - 1 form, 5 itemgroups, 11 items, 1 language
Itemgroups: Administrative documentation, Pharmacogenetic Test, Informed Consent, Pharmacogenetic Test, Collection of blood specimen for laboratory procedure, Pharmacogenetic Test, Informed Consent, Withdraw, Pharmacogenetic Test, Blood specimen, Destruction
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder

Effect of Ritonavir on Bupropion Pharmacokinetics; 103106 - Investigational Product Discontinuation - WELLBUTRIN XL + Ritonavir

- 12/8/19 - 1 form, 2 itemgroups, 3 items, 1 language
Itemgroups: Administrative documentation, Experimental drug, Discontinuation
Study ID: 103106 Clinical Study ID: WXL103106 Study Title:An open-label, 2-period, sequential treatment, 1-way drug interaction study to evaluate the effect of ritonavir on bupropion pharmacokinetics in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: bupropion Trade Name: Wellbutrin,QUOMEM,Elontril,Zyban,ZYNTABAC; Zyban,ZYNTABAC,Wellbutrin,Wellburin,QUOMEM,Prolev,Magerion,Geronplase,Elontril Study Indication: Depressive Disorder